Media Pack
News

Current Edition

JCS Volume 15 Issue 3
 
Regional News

With Tepezza sales still stagnant, Amgen has a plan to boost the newly acquired TED drug

As Amgen’s $27.8 billion buyout of Horizon Therapeutics became official earlier this month, one of the first orders of business for the California biotech giant was ...
2 November 2023 Regional News
Continue Reading →
Regional News

UCB’s approval spree rolls on with FDA nod for Zilbrysq, its 2nd drug for myasthenia gravis

UCB is on an approval roll. Within hours of each other, the Brussels-based company has scored FDA green lights for plaque psoriasis treatment Bimzelx and for general...
19 October 2023 Regional News
Continue Reading →
Regional News

UCB’s blockbuster hopeful Bimzelx overcomes manufacturing hurdles to win FDA nod

UCB has been “eagerly awaiting” FDA approval for its psoriasis therapy Bimzelx (bimekizumab) after manufacturing problems resulted in a rejection last May. Now, the ...
19 October 2023 Regional News
Continue Reading →
Regional News

Takeda ponies up €130M to settle tax linked to distant AbbVie-Shire breakup fee

After years spent challenging a tax break fee tethered to its massive Shire buyout, Takeda has settled with Irish authorities. Takeda will pay €130 million (about...
19 October 2023 Regional News
Continue Reading →
Regional News

After launch limitations, Johnson & Johnson exec touts manufacturing progress on CAR-T drug Carvykti

As Johnson & Johnson and Legend Biotech have sought to grow the reach of their multiple myeloma CAR-T drug Carvykti since winning FDA approval last year, they've...
19 October 2023 Regional News
Continue Reading →
Regional News

Biogen lays off staffers at newly acquired Reata, with 113 set to lose positions

Just two weeks after Biogen completed its buyout of Reata Pharmaceuticals, the combined company is trimming its staff. In a recent Worker Adjustment and Retrainin...
12 October 2023 Regional News
Continue Reading →
Regional News

BMS doubles down on its early-stage partnership with cell therapy manufacturer Cellares

Six weeks after cell and gene therapy manufacturer Cellares revealed that Bristol Myers Squibb would use its innovative robotic production program, the com...
12 October 2023 Regional News
Continue Reading →
Regional News

Bayer christens $250M cell therapy ‘launch facility’ in Berkeley

Despite the promise of cell therapies, manufacturing the personalized medicines at scale has been a limiting factor for many companies. Now, as BlueRock Therapeutics...
11 October 2023 Regional News
Continue Reading →
Regional News

Merck’s Keytruda hits overall survival goal in early lung cancer as FDA decision nears

What doctors described as a “messy” treatment landscape in early-stage non-small cell lung cancer (NSCLC) could get clearer thanks to a first-in-class overall surviv...
11 October 2023 Regional News
Continue Reading →
Regional News

Boehringer Ingelheim embraces dual-pricing tactic with launch of unbranded Humira biosimilar

Boehringer Ingelheim, which recently launched the first interchangeable biosimilar to AbbVie’s megablockbuster Humira, is getting in on the industry’s double-pricing...
5 October 2023 Regional News
Continue Reading →
 

jcs-white.png

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

Facebook Linkedin
Journal For Clinical Studies © 2023, All Rights Reserved – Powered by Teksyte